Citadel Advisors
SGMT icon

Citadel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Citadel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Buy
68,173
+5,054
+8% +$28.2K ﹤0.01% 10083
2025
Q4 		$374K Buy
63,119
+53,078
+529% +$381K ﹤0.01% 9679
2025
Q3 		$68.9K Sell
10,041
-92,742
-90% -$752K ﹤0.01% 12045
2025
Q2 		$783K Buy
102,783
+59,815
+139% +$252K ﹤0.01% 7612
2025
Q1 		$140K Sell
42,968
-701,564
-94% -$2.94M ﹤0.01% 10981
2024
Q4 		$3.35M Sell
744,532
-471,339
-39% -$2.39M ﹤0.01% 4651
2024
Q3 		$3.37M Buy
1,215,871
+20,876
+2% +$64.3K ﹤0.01% 4591
2024
Q2 		$4.09M Buy
1,194,995
+1,164,729
+3,848% +$5.34M ﹤0.01% 4065
2024
Q1 		$164K Buy
+30,266
New +$217K ﹤0.01% 10630
2023
Q4 		– Sell
-311,634
Closed -$2.74M – 15143
2023
Q3 		$2.74M Buy
+311,634
New +$4.15M ﹤0.01% 4642

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's SGMT Position: Q1 2026 in Review

Citadel Advisors increased its Sagimet Biosciences (SGMT) stake by 8% in Q1 2026, buying an estimated $28.2K and bringing the position to 68,173 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10083.

Citadel Advisors first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.09M in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Citadel Advisors held 68,173 shares of Sagimet Biosciences worth $356K as of Q1 2026.
  • Citadel Advisors bought 5,054 Sagimet Biosciences shares in Q1 2026, an estimated $28.2K.
  • Sagimet Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10083 holding.
  • Citadel Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
  • Citadel Advisors's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.